Device Firms Should Get Used To Lower Growth Rates, Analyst Says
This article was originally published in The Gray Sheet
Executive Summary
Growth rates for device use declined precipitously last quarter, and the industry should be prepared for a slow recovery, say Morgan Stanley device sector analysts. What's more, pre-2009 growth rates may be out of reach in the foreseeable future
You may also be interested in...
Medtronic Q1 Revenues Fall 4% On Decreased Hospital Utilization
Medtronic is blaming a 4% decline in corporate first quarter sales on worsening hospital utilization rates in the U.S. The businesses most affected were Cardiac Rhythm Disease Management and Spine, CEO Bill Hawkins reported during an Aug. 24 earnings call
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.